Xenetic Biosciences, Inc. (XBIO)

NASDAQ: XBIO · IEX Real-Time Price · USD
0.730
-0.026 (-3.44%)
May 20, 2022 4:30 PM EDT - Market closed
Market Cap10.82M
Revenue (ttm)1.36M
Net Income (ttm)-5.89M
Shares Out14.83M
EPS (ttm)-0.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume72,192
Open0.800
Previous Close0.756
Day's Range0.730 - 0.800
52-Week Range0.454 - 5.680
Beta2.54
AnalystsBuy
Price Target4.08 (+458.9%)
Earnings DateMay 11, 2022

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug del...

IndustryBiotechnology
Employees4
Stock ExchangeNASDAQ
Ticker SymbolXBIO
Full Company Profile

Financial Performance

In 2021, XBIO's revenue was $1.16 million, an increase of 165.64% compared to the previous year's $436,942. Losses were -$5.65 million, -48.18% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 458.90% from the latest price.

Price Target
$4.08
(458.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical comp...

3 days ago - Accesswire

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potential ...

1 week ago - Accesswire

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Mul...

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the potential...

3 weeks ago - Accesswire

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

- XCARTTM continuing to advance toward IND-enabling studies - PolyXen® platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of cash FRAMINGHAM, MA / ...

1 month ago - Accesswire

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private p...

6 months ago - Accesswire

Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for

Xenetic Biosciences (XBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCART FRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XB...

8 months ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T plat...

8 months ago - Accesswire

5 Penny Stocks Analysts Say To Buy With Targets Up To 300%

Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, News ...

Other symbols:KDMNSBSENSVERB
9 months ago - PennyStocks

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies  Strong royalty growth with PolyXen® platform technology  Bolstered cash position with recently com...

9 months ago - Accesswire

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

9 months ago - Accesswire

XBIO Stock: Xenetic Soars on Private Placement Announcement

XBIO stock is continuing a heck of a week. Just days after it was boosted by Takeda's expansion news, it's looking at a big private sale.

9 months ago - InvestorPlace

Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now

Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:CEMI
9 months ago - PennyStocks

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

FRAMINGHAM, MA / ACCESSWIRE / July 26, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

9 months ago - Accesswire

XBIO Stock: Xenetic Soars on Takeda Expansion News

XBIO stock is racing to the moon today, as Takeda Pharmaceuticals makes an announcement that will see higher demand for Xenetic products. The post XBIO Stock: Xenetic Soars on Takeda Expansion News appe...

9 months ago - InvestorPlace

3 Penny Stocks That Exploded Today, One Up 144%

These penny stocks shot up substantially today; worth it or not? The post 3 Penny Stocks That Exploded Today, One Up 144% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...

Other symbols:MDGSMITQ
9 months ago - PennyStocks

3 Penny Stocks to Watch Making Big Gains Today, One Up 130%

Are these volatile penny stocks worth watching after big gains today? The post 3 Penny Stocks to Watch Making Big Gains Today, One Up 130% appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other symbols:AHPISTRR
10 months ago - PennyStocks

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partn...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study wil...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging P...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at NobleCon17

FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platf...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platfo...

1 year ago - Accesswire

Why Nano-Cap Xenetic Biosciences Is Skyrocketing

Shares of Xenetic Biosciences Inc (NASDAQ: XBIO), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts-based com...

1 year ago - Benzinga